Recognized for pioneering work in area of integrin receptor biology, resulting in new therapies for a number of autoimmune problems
Founder, Director, and Scientific Advisory Board member of Morphic Therapeutic
WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical firm creating a brand new era of oral integrin therapies for the therapy of significant power ailments, immediately applauds Timothy A Springer, PhD for receipt of the 2022 Albert Lasker Basic Medical Research Award. Dr Springer was honored for the invention of integrin receptors, key mediators of mobile interactions in physiology and illness.
The Lasker Awards honor the contributions of leaders who made main advances within the understanding, analysis, therapy, remedy, and prevention of human illness are well known as essentially the most prestigious biomedical analysis awards in America.
Tim Springer receives the Lasker Award for the invention of integrins, a category of transmembrane proteins that permit immune system molecules to stick to their targets. Dr. Springer shares the award with Dr. Richard O. Hynes and Dr. Erkki Ruoslahti who made separate discoveries that, when mixed with Dr. Springer, led to the understanding of your entire integrin receptor household. The discovery and understanding of integrin operate launched analysis and improvement efforts leading to novel therapy strategies for quite a lot of autoimmune problems, neurodegenerative illness, as effectively as clotting and ophthalmic situations.
“The 2022 Lasker Award is a fitting recognition of Tim Springer’s immense contributions to the fields of science and medicine. Tim’s work has led to numerous new treatments for patients suffering from devastating conditions around the world and we extend our deepest congratulations,” mentioned Praveen Tipirneni, CEO of Morphic. “I also thank Tim because without his research in the integrin space, Morphic simply would not exist. Beyond the discovery of the integrin class, Tim continues to drive a deep understanding of the importance of the receptors’ shapes through advanced crystallization methods. Tim has remained a steadfast scientific advisor and strategic counselor to our Company, and I look forward to collaborating with him for years to come.”
About Timothy A. Springer, PhD
Dr. Springer is an immunologist and biophysicist serving as Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. Dr. Springer found integrins and their ligands within the Eighties and since then, has labored on elucidating regulation of their organic operate. His pioneering work resulted within the detailed characterization of integrin construction and sturdy understanding of biophysical phenomena underlying their activation. This has led to the founding of a number of biotechnology corporations (LeukoSite , Scholar Rock, Morphic Therapeutic) and authorised therapeutics together with Amevive®, Raptiva®, Campath®, Velcade®, and Entyvio®. Timothy A. Springer acquired his B.A. in Biochemistry from University of California in 1971, his Ph.D. in Molecular Biology and Biochemistry from Harvard in 1976, and did a fellowship with Cesar Milstein in Cambridge, England.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical firm creating a portfolio of oral integrin therapies for the therapy of significant power ailments, together with autoimmune, cardiovascular, and metabolic ailments, fibrosis, and most cancers. Morphic can be advancing its pipeline and discovery actions in collaborations with Janssen and Schrödinger utilizing its proprietary MInT know-how platform which leverages the Company’s distinctive understanding of integrin construction and biology. For extra info, go to www.morphictx.com.
Cautionary Note Regarding Forward-Looking Statements
This press launch comprises “forward-looking” statements inside the that means of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, together with, however not restricted to: the MInT Platform’s skill to find drug candidates, Morphic’s plans to develop and commercialize oral small-molecule integrin therapeutics and any proposed timing thereof, the initiation, execution and completion of MORF-057 part 2 medical trials, any expectations about security, efficacy, timing and skill to begin or full medical research and/or trials and to acquire regulatory approvals for MORF-057 and different candidates in improvement, the timing of additional information presentation and the flexibility of MORF-057 to deal with inflammatory bowel illness, together with ulcerative colitis, or associated indications. Statements together with phrases such as “believe,” “plan,” “continue,” “expect,” “will be,” “develop,” “signal,” “potential,” “anticipate” or “ongoing” and statements sooner or later tense are forward-looking statements. These forward-looking statements contain dangers and uncertainties, as effectively as assumptions, which, if they don’t totally materialize or show incorrect, might trigger our outcomes to vary materially from these expressed or implied by such forward-looking statements. Forward-looking statements are topic to dangers and uncertainties which will trigger Morphic’s precise actions or outcomes to vary considerably from these expressed in any forward-looking assertion, together with dangers and uncertainties on this press launch and different dangers set forth in our filings with the Securities and Exchange Commission, together with Morphic’s or a companion’s skill to finish a present or future medical trial of any of our present or future product candidates, develop or get hold of regulatory approval for or commercialize any product candidate, Morphic’s skill to guard mental property, the potential influence of the COVID-19 pandemic, and the sufficiency of our money, money equivalents and investments to fund our operations. These forward-looking statements converse solely as of the date hereof and Morphic particularly disclaims any obligation to replace these forward-looking statements or the explanation why precise outcomes would possibly differ, whether or not as a results of new info, future occasions or in any other case, besides as required by regulation.
Contacts
Lasker Foundation Media
Eric M. Gewirtz
[email protected]
+1-212-843-8290
Morphic Therapeutic
Katie Vincett
[email protected]
